Showing results (1921-1930 of 1,956) with videos related to

Sort By:
Pageof 196
Physical Review Letters|February 4, 2014
Measurements of an ablator-gas atomic mix in indirectly driven implosions at the National Ignition FacilityV A Smalyuk, R E Tipton, J E Pino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 TrialA Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 5, 2022
North American tree migration paced by climate in the West, lagging in the EastShubhi Sharma, Robert Andrus, Yves Bergeron, et al.
Physical Review Letters|August 4, 2025
First Demonstration of Improved Fusion Yield with Increased Compression through Reduced Adiabat in Inertial Confinement Fusion Experiments at the National Ignition FacilityM Hohenberger, D S Clark, K D Humbird, et al.
Physical Review. E|March 16, 2024
Design of the first fusion experiment to achieve target energy gain G>1A L Kritcher, A B Zylstra, C R Weber, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker DiscoveryKathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E Lang, Andres Forero-Torres, Douglas Yee, et al.
Nature|December 2, 2016
Quantifying global soil carbon losses in response to warmingT W Crowther, K E O Todd-Brown, C W Rowe, et al.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialKatia Khoury, Jane L Meisel, Christina Yau, et al.
Pageof 196